Statement: U.S. Bill to Import Canadian drugs

Posted on March 7, 2017

Statement

Ottawa,  March 7, 2017 – The following statement can be attributed to Pamela Fralick, President, Innovative Medicines Canada.

“Innovative Medicines Canada is concerned by recent legislative initiatives in the U.S. Congress that could impact the supply of prescription medicines for Canadians. Canada cannot supply medicines and vaccines to a market ten times larger than its own population without endangering Canadian supplies and causing shortages.  Innovative Medicines Canada is committed to working collaboratively with Health Canada and other stakeholders to ensure that Canadian patients continue to have access to the medicines and vaccines that they need.”

About Innovative Medicines Canada

Innovative Medicines Canada is the national voice of Canada’s innovative pharmaceutical industry. We advocate for policies that enable the discovery, development and commercialization of innovative medicines and vaccines that improve the lives of all Canadians. We support our members’ commitment to being valued partners in the Canadian healthcare system.

For further information:

Sarah Dion-Marquis
Media Relations
Telephone: (613) 769-6510
sdmarquis@imc-mnc.ca

Leave a Reply

Your email address will not be published. Required fields are marked *